Miss Serkalem Merra, | |
6475 New Hampshire Ave Ste 500a, Hyattsville, MD 20783-3295 | |
(301) 560-1352 | |
Not Available |
Full Name | Miss Serkalem Merra |
---|---|
Gender | Female |
Speciality | Home Health Aide |
Location | 6475 New Hampshire Ave Ste 500a, Hyattsville, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366792822 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Miss Serkalem Merra, 6475 New Hampshire Ave Ste 500a, Hyattsville, MD 20783-3295 Ph: (301) 560-1352 | Miss Serkalem Merra, 6475 New Hampshire Ave Ste 500a, Hyattsville, MD 20783-3295 Ph: (301) 560-1352 |
News Archive
Roughly one out of three kids screened for high cholesterol between the ages of 9 and 11 has borderline or high cholesterol, potentially placing them at greater risk for future cardiovascular disease, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.
Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.
Samples of smoke particles emanating from burning roadside trash piles in India have shown that their chemical composition and toxicity are very bad for human health.
Repros Therapeutics (NasdaqGM:RPRX) today announced that on September 15, 2009, the Company received a second letter from The Nasdaq Stock Market advising that, in addition to the deficiencies previously disclosed on August 17, 2009, the Company's market value of publicly held shares was below the minimum $15,000,000 requirement for continued listing on the Nasdaq Global Market by Listing Rule 5450(b)(2)(C) or 5450(b)(3)(C).
› Verified 7 days ago